New Paper Underscores Inflammation’s Role in Atherosclerosis

Understanding the Effect of Inflammation is Key for Early Intervention, Reducing Adverse Cardiovascular Outcomes

The International Atherosclerosis Society today released a clinical proceedings white paper outlining the role of inflammation in atherosclerosis and the importance of early intervention.

The paper has four main sections:

  • The role of inflammation in atherosclerosis is explained, noting that local inflammation in the artery wall participates directly in the development of the condition. Systemic, chronic inflammation can also promote the advancement of atherosclerosis and increase the risk of developing cardiovascular diseases.
  • Using biomarkers to identify inflammatory risk in individual patients is now possible. Assessing levels of high-sensitivity CRP specifically can be used to help determine therapeutic strategies that may reduce the risk of major cardiovascular events.
  • Interventions that may mitigate inflammatory risk include lifestyle modifications as well as pharmaceutical interventions. Policy changes could also mitigate the inflammatory risk of atherosclerosis.
  • The burdens of disease are substantial. Atherosclerosis results in significant loss of life and greatly impacts household finances and economies worldwide.

Assessment & Treatment of Inflammation in Atherosclerosis is authored by four international experts:

  • Peter Libby, MD – USA
  • Wolfgang Koenig, MD, FRCP, FESC, FACC, FAHA – Germany
  • Jessica M. Peña, MD, MPH, FACC, FNLA – USA
  • Hiroaki Shimokawa, MD, PhD – Japan

READ WHITE PAPER: Assessment & Treatment of Inflammation in Atherosclerosis


Peter Libby, MD, President, of the International Atherosclerosis Society and Chair of the White Paper Expert Panel said, “Atherosclerosis is a primary cause of cardiovascular disease, the leading cause of death worldwide. This paper underscores the persistent need for a more complete understanding of the role of inflammation in atherosclerosis progression among physicians globally, how to identify such inflammation, and how to mitigate the inflammation-associated risk of adverse cardiovascular events. These steps are of the utmost importance for the development of effective treatment strategies that can reduce the morbidity and mortality caused by atherosclerotic cardiovascular disease.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”